DA
CORT icon

Duality Advisers’s Corcept Therapeutics CORT Stock Holding History

Duality Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-89,188
Closed -$2.25M – 125
2024
Q1 		$2.25M Buy
89,188
+77,346
+653% +$1.83M 0.22% 162
2023
Q4 		$385K Buy
11,842
+273
+2% +$7.5K 0.04% 466
2023
Q3 		$315K Sell
11,569
-22,324
-66% -$646K 0.04% 480
2023
Q2 		$754K Buy
+33,893
New +$780K 0.09% 332
2023
Q1 		– Sell
-51,409
Closed -$1.04M – 594
2022
Q4 		$1.04M Buy
51,409
+33,875
+193% +$849K 0.12% 304
2022
Q3 		$450K Buy
+17,534
New +$469K 0.05% 432

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Duality Advisers's CORT Position: Q2 2024 in Review

Duality Advisers sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 89,188 shares — an estimated $2.25M sold.

Duality Advisers first reported a position in CORT in Q3 2022 and held it in 6 quarters. The position peaked at $2.25M in Q1 2024. 285 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Duality Advisers reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 89,188 Corcept Therapeutics shares in Q2 2024, an estimated $2.25M.
  • Duality Advisers first reported a position in Corcept Therapeutics in Q3 2022 and held it in 6 quarters.
  • Duality Advisers's Corcept Therapeutics position peaked at $2.25M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.